HT
FOLD

Headlands Technologies’s Amicus Therapeutics FOLD Stock Holding History

Headlands Technologies’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-161,159
Closed -$1.27M – 724
2025
Q3 		$1.27M Buy
161,159
+1,637
+1% +$11.7K 0.1% 200
2025
Q2 		$914K Buy
159,522
+103,492
+185% +$668K 0.11% 197
2025
Q1 		$457K Buy
56,030
+21,218
+61% +$196K 0.05% 304
2024
Q4 		$328K Buy
34,812
+29,832
+599% +$310K 0.03% 429
2024
Q3 		$53.2K Sell
4,980
-3,967
-44% -$43.2K 0.01% 794
2024
Q2 		$88.8K Buy
+8,947
New +$91.8K 0.01% 673

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Headlands Technologies's FOLD Position: Q4 2025 in Review

Headlands Technologies sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 161,159 shares — an estimated $1.27M sold.

Headlands Technologies first reported a position in FOLD in Q2 2024 and held it in 6 quarters. The position peaked at $1.27M in Q3 2025. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Headlands Technologies reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Headlands Technologies sold 161,159 Amicus Therapeutics shares in Q4 2025, an estimated $1.27M.
  • Headlands Technologies first reported a position in Amicus Therapeutics in Q2 2024 and held it in 6 quarters.
  • Headlands Technologies's Amicus Therapeutics position peaked at $1.27M in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Headlands Technologies's 13F filing for Q4 2025, filed 13 Feb 2026.